CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The management of lower-grade gliomas (Diffuse low-grade and intermediate-grade gliomas, WHO
II and III) is largely based on surgery followed by radiotherapy. Recent studies showed that
lower-grade glioma patients with IDH wild-type (IDH-wt) and TERT promoter mutation
(TERTp-mut) had dismal clinical outcomes. These results suggested that current treatment
strategies are not adequate for this subtype of lower-grade glioma.
The present study aims to examine the efficacy and safety of concurrent chemoradiotherapy
with temozolomide followed by adjuvant temozolomide for lower- grade glioma patients with
IDH-wt and TERTp-mut.
Phase:
Early Phase 1
Details
Lead Sponsor:
Beijing Tiantan Hospital
Collaborators:
Beijing Neurosurgical Institute Beijing Shijitan Hospital Beijing Shijitan Hospital, Capital Medical University